AKT1 and systemic lupus erythematosus: The multi-target and multi-level interventional advantages of hyperoside highlighted in our work offer fresh insights into its mechanism of action in SLE-related renal injury and establish an experimental foundation for developing therapeutics targeting the AKT1 signaling pathway.